Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Coya Therapeutics is a clinical-stage biotech focused on developing therapies that enhance regulatory T cell (Treg) function to treat neurodegenerative, autoimmune, and metabolic diseases. Its core products include biologics, Treg-derived exosomes, and autologous Treg cell therapies, targeting immune dysregulation. The company leverages innovative combination approaches, aiming to restore immune balance and address high unmet medical needs in complex inflammatory conditions.
This description was generated via AI from an annual report. Updated about 1 year ago.